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Abstract
Background: The cyclin-dependent kinase (CDK) and mitogen-activated protein kinase (MAPK) mediated
phosphorylation of glucocorticoid receptor (GR) exerts opposite effects on GR transcriptional activity and affects
other posttranslational modifications within this protein. The major phosphorylation site of human GR targeted by
MAPK family is the serine 226 and multiple kinase complexes phosphorylate receptor at the serine 211 residue. We
hypothesize that GR posttranslational modifications are involved in the determination of the cellular fate in human
lymphoblastic leukemia cells. We investigated whether UV signalling through alternative GR phosphorylation
determined the cell type specificity of glucocorticoids (GCs) mediated apoptosis.
Results: We have identified putative Glucocorticoid Response Elements (GREs) within the promoter regulatory
regions of the Bcl-2 family members NOXA and Mcl-1 indicating that they are direct GR transcriptional targets.
These genes were differentially regulated in CEM-C7-14, CEM-C1-15 and A549 cells by glucocorticoids and JNK
pathway. In addition, our results revealed that the S211 phosphorylation was dominant in CEM-C7-14, whereas the
opposite was the case in CEM-C1-15 where prevalence of S226 GR phosphorylation was observed. Furthermore,
multiple GR isoforms with cell line specific patterns were identified in CEM-C7-14 cells compared to CEM-C1-15
and A549 cell lines with the same antibodies.
Conclusions: GR phosphorylation status kinetics, and site specificity as well as isoform variability differ in CEM-C7-
14, CEM-C1-15, and A549 cells. The positive or negative response to GCs induced apoptosis in these cell lines is a
consequence of the variable equilibrium of NOXA and Mcl-1 gene expression potentially mediated by alternatively
phosphorylated GR, as well as the balance of MAPK/CDK pathways controlling GR phosphorylation pattern. Our
results provide molecular base and valuable knowledge for improving the GC based therapies of leukaemia.
Background
Glucocorticoid hormones (GCs) are widely used for the
treatment of medical conditions such as asthma and
pulmonary diseases, inflammatory bowl disease, rheuma-
toid arthritis and Acute Lymphoblastic Leukaemia (ALL)
[1-5]. The ability of GCs to suppress inflammation and
induce apoptosis is the main factor contributing to their
therapeutic activity.
GCs exert most of their physiological responses by
binding to and modulating the transcriptional activity of
the glucocorticoid receptor (GR). GR is a member of
the subfamily of steroid receptors that is part of the
superfamily of nuclear receptors. GR binding to the Glu-
cocorticoid Response Elements (GREs) present in the
promoters of its target genes is the mechanism by
which the expression of these genes is regulated by glu-
cocorticoids. Positive and negative GREs [6,7], protein-
protein interactions between GR and its numerous co-
factors [3,8-10] and with other transcription factors
such as AP-1, NF-B, CREB, and GATA-1 determine
the outcome of the GR mediated regulation of gene
expression [2,4,6,9]. Posttranslational modifications of
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cificity and involve several cell-signalling cascades [10].
Phosphorylation sites have been identified in the N
terminal transactivation domain and S211 is targeted by
CDK and p38 kinases whereas S226 is phosphorylated
by JNK pathway. Phosphorylation of the receptor modu-
lates its transcriptional activity, alters its protein stability
and subcellular location [11-14]. GR phosphorylation
appears to be cell cycle dependent [15,16] and has been
shown recently to be clinically relevant [17]. The con-
clusions from several studies indicate that UV activated
JNK and p38 MAPKs affect GR transcriptional activity
and specificity in a cell type and target gene dependent
manner [10,13] and hence resistance to GCs dependent
apoptosis might derive from aberrant changes in these
signalling pathways.
The current concept for GR-dependent apoptosis in
leukaemia entails the presence of a transcriptionally
competent GR [18,19] and accumulating evidence sug-
gests that dexamethasone-induced apoptosis in lympho-
cytes is executed through the intrinsic pathway
[3,6,8,20,21]. In agreement with these observations,
knockouts of various Bcl-2 family members such as Bim
[22], Puma or NOXA [23], or double knockouts of Bax
and Bak confer resistance to GC mediated apoptosis in
thymocytes [24]. Furthermore, microarray analysis has
revealed that several pro-apoptotic members of the Bcl-
2 family, such as the BH3-only molecules BMF, Bim
and NOXA are induced, whereas anti-apoptotic mem-
bers of this family are repressed in a glucocorticoid
dependent manner [25-28]. The molecular mechanisms
by which GR regulates apoptosis in a cell-type specific
manner have been a subject of intense research and
recently the important role of the balance of the Bcl-2
family genes determining the outcome of the GC depen-
dent apoptotic events has been suggested [27].
Mutations or alterations in GR protein levels are
uncommon in primary leukaemia cells from GC-resis-
tant patients [29] therefore suggesting that signalling
p a t h w a y sa r el i k e l yt op l a yar o l ei nm o d u l a t i n gG R
phosphorylation and activity and in determining resis-
tance or sensitivity to GCs induced apoptosis. In addi-
tion, phosphorylation affecting the interaction and
subcellular localisation of the Bcl-2 family members
eventually leading to the blockade of apoptosis and
hence resistance to glucocorticoids in leukaemia has
been proposed as possible mechanism favouring antia-
poptotic state in leukaemic cells [30].
Knockdown of the anti-apoptotic Bcl-2 family member
Myeloid Cell Leukaemia sequence 1 (Mcl-1) has been
shown to sensitise Acute Lymphoblastic Leukaemia
(ALL) cell lines to GC-induced apoptosis [31] and is
also implicated in resistance to GC-induced apoptosis in
human neutrophils [32]. A critical role for the Mcl-1
function appears to be its interaction with other Bcl-2
family members and the pro-apoptotic Bcl-2 family
member NOXA is essential in triggering Mcl-1 degrada-
tion [33].
In this study, we have investigated the role of gluco-
corticoids in the regulation of NOXA and Mcl-1 func-
tion in epithelial or lymphoid cell lines and we
identified GR transcriptional involvement in the expres-
sion of both NOXA and Mcl-1. In addition, we provide
evidence that NOXA and Mcl-1 expression is selectively
regulated in cell types that are sensitive or resistant to
glucocorticoid-induced apoptosis. Furthermore, our
results demonstrate that JNK pathway activated by UV
radiation alters glucocorticoid dependent transcriptional
regulation of Mcl-1, Noxa and Bim and modulates GR
phosphorylation pattern as well as cell cycle progression
and apoptosis suggesting that these events could be
important factors determining sensitivity or resistance to
GC-induced apoptosis.
Results
The regulatory regions of the promoters of Mcl-1 and
NOXA genes bear functional GREs
The regulation of the balance of anti-apoptotic and pro-
apoptotic members of the Bcl-2 family determines the
cellular fate in the glucocorticoid mediated apoptosis
[27]. Mcl-1 and Noxa have been proposed as major reg-
ulators of the glucocorticoid mediated pro- or anti-
apoptotic events [34]. Therefore, we investigated
whether GR was involved in the transcriptional regula-
tion of the expression of those two genes. Towards this
direction, we searched for the possible existence of
GREs in the promoters of NOXA and Mcl-1 genes
using the consensus GRE sequence described by Wang
at al., 2004 [35]. Putative GREs were identified within
the promoters of both genes. To test whether these
GREs were functional, we generated luciferase reporter
constructs using a ~400 bp DNA fragment from the
promoters of Mcl-1 (-1973 to -1573) and NOXA (-982
to -609) containing wild type GREs or their mutated
counterparts, which we constructed as described in the
Figure 1A. Luciferase reporter assays were carried out in
A549 human lung cancer cells. Hormone induced ~1.5-
fold increase in the luciferase expression driven by the
wild type Mcl-1 promoter, whereas in the case of the
NOXA wild type reporter there was ~1.5 fold reduction
of luciferase expression. Mutation of the NOXA and
Mcl-1 GREs rendered the constructs unresponsive to
dexamethasone treatment (Figure 1B and 1C). The
extensively characterised GR transcription target TAT-
luciferase reporter was used as control in these experi-
ments (Figure 1D).
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In order to analyse the cellular effects of the GR
mediated transcriptional regulation of Mcl-1 and
NOXA, we exploited the ALL cell lines CEM-C7-14 and
CEM-C1-15 that are sensitive or resistant to the GC
mediated apoptosis respectively. For this purpose, we
examined the effects of glucocorticoids on the Mcl-1,
NOXA and Bim mRNA levels, in CEM-C7-14 and
CEM-C1-15 cells (Figures 2 and 3). Given the fact that
phosphorylation of glucocorticoid receptor modulates its
multiple functions in a target gene specific manner
[10,12,13,15,16] we investigated whether UV dependent
phosphorylation of GR resulted in selective modulation
of Mcl-1, NOXA or Bim gene expression. For this pur-
pose, UV irradiation was used to activate JNK mediated
phosphorylation of GR and the effects of this activation
on the Mcl-1, NOXA and Bim gene expression were
analysed by qRT-PCR (Figures 2, 3, 4). The effects of
glucocorticoid receptor activation on endogenous Mcl-1,
NOXA and Bim genes were analysed in cells treated
with the synthetic glucocorticoid dexamethasone for 2,
6 and 24 hours. Dexamethasone treatment of CEM-C7-
14 cells resulted in a two-fold increase of Mcl-1 mRNA
levels (Figure 2, diamonds). Surprisingly, combinatorial
treatment of these cells with dexamethasone and with
either UV or JNK inhibitor SP600125 produced similar
stimulatory effect on the Mcl-1 mRNA expression in
the first 6 hrs whereas JNK inhibitor further activated
Mcl-1 gene expression at 24 hr of treatment (Figure 2,
compare squares to circles respectively). NOXA gene
expression was marginally reduced by dexamethasone
treatment alone whereas MAPK dependent phosphory-
lation increased NOXA gene expression in CEM-C7-14
cell line (Figure 2, compare diamonds to squares). The
addition of SP600125 kinase inhibitor to the UV treated
CEM-C7-14 cells reduced the mRNA levels of this pro-
apoptotic gene compared to the UV treatment alone at
shorter treatments (Figure 2, compare squares to cir-
cles). Finally, Bim mRNA levels increased 10 fold 24 h
Figure 1 NOXA and Mcl-1 bear functional GREs. A, Schematic representation describing construction of luciferase reporter plasmids
containing wt and mutant human NOXA and Mcl-1 GRE promoter fragments. The numbers above the constructs indicate the region of the
promoter relative to the transcription start site. Mutated bases are underlined. A549 cells were either transfected with NOXA-GREwt or NOXA-
GREmut (B), Mcl-1-GREwt or Mcl-1-GREmut (C) and TAT3 (D) luciferase reporter constructs. Cells were treated with Dex (100 nM) for 16 h and
luciferase assays were performed [53]. The graphs represent relative luciferase to b-galactosidase activity and data is the average of 5
independent experiments.
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lower panel, diamonds). UV treatment had negative
effect on Bim mRNA expression and this downregula-
tion was partially reversed by treating the sensitive
CEM-C7-14 cells with the kinase inhibitor (Figure 2,
lower panel, compare squares to circles respectively).
The results shown in Figure 3 indicated two fold
increase of Mcl-1 mRNA levels after dexamethasone
treatment whereas combination of dexamethasone and
UV treatments led to initial increase after two hours
and significant further reduction in CEM-C1-15 cells
(Figure 3, compare diamonds with squares). The use of
SP600125 inhibitor revealed that Mcl-1 mRNA levels in
UV treated cells were regulated by JNK mediated phos-
phorylation in a complex manner (Figure 3, circles).
Hormone treatment increased NOXA mRNA levels
after 6 and 24 h. Interestingly, when these cells were
treated with UV, NOXA mRNA levels increased three
fold at 6 h and dropped 24 h after dexamethasone addi-
tion to lower levels than those in dexamethasone alone
treated cells (Figure 3, compare diamonds to squares at
24 h). The SP600125 inhibitor partially reversed the UV
effect and NOXA mRNA levels under these conditions
were close to basal levels (Figure 3, compare circles to
squares), indicating that phosphorylation is important
for events mediating NOXA gene expression and that
JNK pathway was playing a role in this process in CEM-
C1-15 cells. Significant increase in Bim mRNA levels
was observed 24 h after hormone addition in CEM-C1-
15 cells exposed to UV irradiation and this effect was
completely abolished by SP600125 (Figure 3, lower
panel, compare squares to circles respectively) signifying
that JNK phosphorylation was important in the regula-
tion of Bim gene expression.
To address tissue specific effects of glucocorticoid
receptor activation, endogenous Mcl-1 and NOXA
genes were analysed by monitoring their mRNA levels
in A549 cells treated as above (Figure 4). Five-fold
increase in Mcl-1 expression after 24 hr treatment of
A549 cells with hormone was detected (Figure 4, dia-
monds) whereas NOXA gene expression was weakly
repressed (Figure 4, diamonds). As a control treatment,
we followed the Bim gene expression, as this gene is
known to be an indirect glucocorticoid receptor target
inducing apoptosis [28]. Bim expression increased sub-
stantially in the 24 h ligand treated cells (Figure 4, lower
Figure 2 Dexamethasone regulates NOXA/Mcl-1 mRNA levels in CEM-C7-14 cells. CEM-C7-14 cell were cultured in DCC-treated media and
incubated with either dexamethasone (1 μM) alone or combination of dexamethasone (1 μM) with UV irradiation or SP600125 inhibitor as
described in Material and Methods and [10] for the times indicated. Cells were lysed and total mRNA was extracted as described in Materials
and Methods, reverse transcribed and subjected to qRT-PCR for Mcl-1, NOXA and Bim. All results have been normalised to Rpl19, which was
used as an internal control. The data shown is representative of three independent experiments.
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activated NOXA (Figure 4, squares). Bim gene expres-
sion was reduced in cells treated with dexamethasone
for 6 h in combination with UV irradiation and was ele-
vated in UV treated cells incubated in the absence of
hormone (Figure 4, squares). Inhibition of JNK kinase
activity by SP600125 had marginal effect on the Mcl-1
and NOXA gene expression in A549 cells, whereas it
completely abolished Bim gene expression (Figure 4, cir-
cles). Taken together the results shown in Figure 4
imply that GR is involved in the transcriptional modula-
tion of Mcl-1 and NOXA genes in A549 cells and that
this regulation is UV sensitive.
In conclusion, Bim in CEM-C1-15 was activated and
in CEM-C7-14 cells was inhibited by UV dependent
phosphorylation and this effect was mediated at least in
part by GR and JNK pathways. Bim expression was sen-
sitive to dexamethasone and JNK inhibitor treatments.
Mcl-1 gene expression increased at 2 hrs after Dexa-
methasone and UV and decreased after longer treat-
ments in CEM-C1-15 cells (Figure 3), whereas UV
activated hormone dependent effects on Mcl-1 gene
expression in CEM-C7-14 cells (Figure 2). The effect of
UV on NOXA gene expression differed between CEM-
C7-14 and CEM-C1-15 cells since the 24 hrs treatments
in the first case increased and in the second decreased
NOXA gene expression displaying differential sensitivity
to JNK mediated events in the two cell lines. Taken
together the results presented in Figures 2, 3 and 4 sug-
gested that GR dependent transcriptional regulation of
Mcl-1 and NOXA gene expression is cell type specific
and that the magnitude and the direction of this control
is sensitive to UV radiation and JNK activation. These
effects are most likely result of direct transcriptional
regulation by GR since mRNA levels for both Mcl-1 and
NOXA genes did not decrease substantially up to 6 hrs
of treatment with dexamethasone in the absence or pre-
sence of cyclohexamide (Additional file 1).
In order to substantiate these results we monitored
the protein levels of the three Bcl-2 family members
Mcl-1, NOXA and Bim in CEM-C7-14, CEM-C1-15 and
A549 cells (Figure 5). In CEM-C7-14 cells, GR, Mcl-1
and Bim protein levels were upregulated 24 hrs after
hormone treatment (Figure 5A, lane 4). Initially
increased NOXA protein levels following 2 hrs hormone
treatment were observed (Figure 5A, NOXA, lane 2)
Figure 3 Dexamethasone regulates NOXA/Mcl-1 mRNA levels in CEM-C1-15 cells. CEM-C1-15 cells were cultured in DCC-treated media and
incubated as described above for CEM-C7-14 cells. Cells were lysed and total mRNA was extracted as described above and subjected to qRT-PCR
for Mcl-1, NOXA and Bim. All results have been normalised to Rpl19, which was used as an internal control. The data shown is representative of
three independent experiments.
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ure 5A, NOXA, compare lane 2 to 4) in agreement with
previously published results [27,28]. In CEM-C1-15
cells, Mcl-1, NOXA, and Bim protein levels remained
relatively unchanged irrespectively of the duration of the
hormone treatment whereas GR protein levels increased
after 2 hours of hormone treatment (Figure 5B, lanes 1-
4). In A549 cells Mcl-1 protein levels were upregulated
(Figure 5C, Mcl-1) whereas NOXA protein levels were
downregulated after 24 h treatment with dexamethasone
(Figure 5C, NOXA, lane 4). Bim protein levels did not
change and GR was weakly downregulated at 24 hours
of treatment after initial increase at shorter treatments
(Figure 5C, GR lanes 1-4). To conclude, Mcl-1 protein
levels increased in CEM-C7-14 and A549 cells and were
unchanged in CEM-C1-15 cells. NOXA protein levels
decreased in CEM-C7-14 and A549 whereas remained
unaltered in CEM-C1-15 cells. Bim protein levels
increased only in CEM-C7-14 cells.
Glucocorticoid receptor is differentially phosphorylated in
UV irradiated CEM-C7-14, CEM-C1-15 and A549 cells
Kinase pathways affecting GR phosphorylation have
been implicated as an important factor in determining
the effects of glucocorticoids [10,13]. Our results sug-
gested that UV and JNK activation play a role in deter-
mining GR transcriptional activity (Figures 2, 3, 4, and
[10]). In an attempt to analyse GR phosphorylation at
S226 and S211 target sites, CEM-C7-14 cell lines were
UV irradiated to activate the MAPK pathway [10] or
were treated with the SP600125 inhibitor of JNK activity
in the presence or absence of dexamethasone for differ-
ent time intervals as shown in Figure 6A. Two GR
bands were observed after probing with GR specific
antibodies in CEM-C7-14 cells, perhaps due to the exis-
tence of multiple GR isoforms carrying other posttran-
slational modifications in addition to S211
phosphorylation, or other mechanisms. We observed
that the total GR protein levels and S211 phosphoryla-
tion gradually increased with hormone treatment in the
presence or absence of the SP600125 inhibitor, whereas
the phosphorylation levels of GR at S226 were generally
low and followed the total GR protein levels (Figure 6A,
lanes 1-4 and 9-12). UV treatment alone or in combina-
tion with hormone resulted in general decrease of the
total and both phosphorylated GR isoforms (Figure 6A,
lanes 5-8 and 13-15 respectively). Total and phosphory-
lated JNK levels were used as control for the MAPK
activity and actin as loading mark for equal protein
amounts (Figure 6A). Comparative densitometric analy-
sis of the GR phosphorylation levels indicated preva-
lence of GR phosphorylation at the S211 residue versus
the S226 in the CEM-C7-14 cells (Figure 6A, lower
panel). Furthermore, the possibility of the existence of
Figure 4 Dexamethasone regulates NOXA/Mcl-1 mRNA levels in A549 cells. A549 cells were cultured in DCC-treated media and incubated
as described in Figure 2 above for CEM-C7-14 cells. Cells were lysed and total mRNA was extracted as described in above and subjected to qRT-
PCR for Mcl-1, NOXA and Bim. All results have been normalised to Rpl19, which was used as an internal control. The data shown is
representative of three independent experiments.
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not be excluded as more than one band was detected in
immunoblots indicated by arrows (Figure 6A, arrows).
The bands specified with arrows in Figure 6A were con-
sidered for the quantification presented in Figure 6A,
lower panel.
In CEM-C1-15 cells, the total GR protein levels
increased two hours after hormone treatment alone or in
combination with SP600125 inhibitor and remained rela-
tively unaltered with prolonged treatments (Figure 6B,
lanes 1-4 and 9-12). In cells treated with combination of
hormone with UV or UV alone decrease in total GR pro-
tein levels was observed (Figure 6B, lanes 5-8 and 13-15
respectively). In contrast to CEM-C7-14 in CEM-C1-15
cells, the levels of GR phosphorylation at S226 did not fol-
low the total GR protein levels (Figure 6B). Phosphoryla-
tion of GR at S211 increased 2 hours after the addition of
hormone and did not significantly change in cells treated
with hormone/SP600125 or hormone/UV (Figure 6B). In
cells treated with UV in the absence of hormone basal
levels of S211 GR phosphorylation were detected (Figure
6B, lanes 13-15). Total JNK protein levels and its activity
measured by its phosphorylation status, together with
actin loading control are displayed in Figure 6B. Densito-
metric scanning of these results and normalization of
phosphorylation levels to the total GR levels indicated that
S226 phosphorylation was the highest in the absence of
hormone and revealed overall predominant or equal phos-
phorylation of the S226 over the S211 GR phosphorylation
(Figure 6B, lower panel). The bands specified with arrows
in Figure 6B were quantified and results presented in the
diagram (Figure 6B, lower panel).
The fact that CEM-C1-15 cell lines are resistant and
the CEM-C7-14 are sensitive to glucocorticoid induced
apoptosis prompted us to investigate the phosphoryla-
tion pattern of the receptor in another cell line namely
the A549 human lung epithelial cells [36]. The reason
for monitoring the GR phosphorylation pattern in A549
cells was to test whether cell type influences links
between GR phosphorylation and resistance or sensitiv-
ity to glucocorticoid-stimulated apoptosis (Figure 6C).
The results shown in Figure 6C indicated that GR pro-
tein abundance in A549 cells decreased upon hormone
treatment alone or in combination with UV or JNK
inhibitor (Figure 6C, lanes 1-12). UV irradiation did not
change significantly total GR protein levels (Figure 6C,
lanes 5-8 and 13-15). S226 phosphorylation increased
upon 2 and 6 hours of hormone treatment and slightly
decreased after 24 hrs of Dex treatment (Figure 6C,
lanes 1-4). Significant increase in S226 phosphorylation
was observed in cells treated with UV alone compared
to non treated cells (Figure 6C, lower panel, compare
black bar 1 with bar 5) and after 24 hrs treatment with
combination of UV and hormone compared to indivi-
dual treatments (Figure 6C, lower panel, compare black
bar 1 with black bar 5 and black bars 4 and 15 with
black bar 8). S211 phosphorylation gradually decreased
after initial increase in cells treated with hormone for 2
hrs (Figure 6C, lanes 1-12). In UV irradiated A549 cells,
phosphorylation of GR at S211 remained low at the
basal level (Figure 6C, lanes 13-15). The bands specified
with arrows in Figure 6C were quantified and results
presented in the diagram (Figure 6C, lower panel).
Quantification of these results suggested that in most
cases S211 and S226 residues were phosphorylated to
similar extent, except in the UV treated cells where S226
phosphorylation was more intense than S211 (Figure 6C,
lower panel, compare black to white bars). Taken
Figure 5 Dexamethasone regulates NOXA/Mcl-1 protein levels. CEM-C7-14 (A), CEM-C1-15 (B) and A549 (C) cells were cultured in DCC-
treated media and incubated with dexamethasone (1 μM) for the times indicated. Cells were lysed and total cell protein extracts were subjected
to western blot analysis. Mcl-1, NOXA, Bim and GR (2F8 antibody) were detected using specific antibodies against these proteins. Actin was used
as loading control.
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cells were cultured in DCC-treated media and incubated with dexamethasone (1 μM) (lanes 1-12), UV (lanes 5-8 and 13-15) and the SP600125
inhibitor (lanes 9-12) for the times indicated. Cells were treated with UV or JNK inhibitor and collected after 30 min in lanes 5 and 9, or after
indicated time. Cells were lysed and total cell protein extracts were subjected to western blot analysis using the specific antibody 2F8 against
total GR (T-GR), phosphorylated GR at S226 (S226) and S211 (S211), total JNK (T-JNK, JNK2/3 54 kDa and JNK1 46 kDa) and phosphorylated JNK
(P-JNK). The bands indicated by arrow were taken into account for the quantification shown in the bottom of A, B and C. Actin was used as
loading control.
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GR phosphorylation in the three cell lines as detected by
altered phosphorylation and kinetic patterns of CDK and
JNK dependent GR target residues.
Glucocorticoid mediated apoptosis is cell type specific
To determine the apoptotic effect that glucocorticoids
have on various cell lines, we treated CEM-C7-14,
CEM-C1-15, A549, and HeLa cell lines with dexametha-
sone and performed flow cytometry (Figure 7 and data
for HeLa not shown). The lymphoblastic leukaemia
CEM-C7-14 cells are sensitive to glucocorticoid-induced
apoptosis, whereas the CEM-C1-15 cell line is a selected
in vitro subclone of the CEM-C7-14 resistant to GC
mediated apoptosis [37]. Although A549 lung carcinoma
cells have been extensively studied with respect to GR,
inconclusive results have been reported in terms of their
response to glucocorticoid induced apoptosis, although
previous reports have shown that ectopic GR expression
induces apoptosis in these cells [36]. In CEM-C1-15 and
A549 the percentage of cells in the sub-G1 phase was
mostly below 10%, and a slight decrease in S phase of
the cell cycle 48 h after dexamethasone treatment was
observed (Figure 7A and 7C). In the case of CEM-C7-14
cells, prolonged hormone treatment resulted in the
increase of the apoptotic population and concomitant
decrease in the number of cells entering the S-phase of
the cell cycle (Figure 7A, C and Additional file 2).
The effect of phosphorylation on the apoptotic profile of
CEM-C7-14 cells was investigated by treating UV irra-
diated or not irradiated cells with dexamethasone for
the indicated times and subjecting them to FACS analy-
sis. As shown in Figure 8A the longer treatment with
dexamethasone increased the Sub-G1 population from
21% in 0 h to 56% in 48 h dexamethasone treated cells.
Further increase of the apoptotic population of CEM-
C7-14 cells was observed with combination of UV irra-
diation and hormone treatment for the time points
tested. In particular, only a quarter of the UV irradiated
CEM-C7-14 cells was alive after 48 h of dexamethasone
treatment, whereas half of dexamethasone only treated
cells was still alive after 48 h treatment (Figure 8A,
compare profile 5 with 10).
S i n c eN O X Am R N Ae x p r e s s i o nw a sd i f f e r e n t i a l l y
regulated in UV treated CEM-C7-14 and CEM-C1-15
cells (Figures 2 and 3) we decided to investigate
Figure 7 CEM-C7-14 cells accumulate in Sub-G1 phase after prolonged hormone treatment. CEM-C1-15, CEM-C7-14 and A549 cells (white,
black and grey bars respectively) cultured in DCC-treated media incubated with Dex (1 μM) for the times indicated and FACS analysis
performed as described previously [53]. Sub-G1 (A), G1 (B), S (C) and G2 (D) cell cycle phase profiles are representative of three independent
experiments.
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the glucocorticoid-induced apoptosis. For this purpose,
we used the proteasome inhibitor, MG-132, which has
been shown to significantly induce NOXA [38] to treat
CEM-C1-15 and CEM-C7-14 cells in the presence or
absence of dexamethasone and determined the percen-
tage of cells that had undergone apoptosis using flow
cytometry (Figure 8B). As expected hormone treatment
alone did not have any effect on apoptosis in CEM-
C1-15 cells (Figure 8B compare white bars 1 and 2).
Addition of MG-132 increased dramatically the Sub-
G1 population in both cell lines (Figure 8B, compare
bars 1 and 3), whereas combination of dexamethasone
with MG-132 increased only the number of CEM-C7-
14 cells undergoing apoptosis (Figure 8B, compare bars
3 and 4). In particular dexamethasone treatment
increased by threefold the Sub-G1 population of CEM-
C7-14 cells (Figure 8B, compare black bars 1 and 2).
Combination of dexamethasone with MG-132
increased further the net apoptotic effect of MG-132
by 20% only in the CEM-C7-14 cells (Figure 8B, com-
pare black bars 3 and 4) implying that NOXA contri-
butes to the GC induced apoptosis only in CEM-C7-14
cells (Additional file 3).
Figure 8 A. UV irradiation enhances the proapoptotic effect of dexamethasone in CEM-C7-14 cells. Determination of the cell cycle
profiles of CEM-C7-14 cells UV irradiated (6-10) or not irradiated (1-5) in the presence (2-5 and 7-10) or absence (1 and 6) of dexamethasone for
the indicated times. FACS experiments were performed two times and the profiles shown are from one experiment. B. MG132 enhances
glucocorticoid-induced apoptosis. CEM-C1-15 (white bars) and CEM-C7-14 cells (black bars) were cultured in DCC-treated media incubated
with dexamethasone (1 μM for 48 hr) (bars 2 and 4) in the presence of MG-132 (1 μM, 24 hr) (bars 3 and 4) and FACS analysis performed. Data
is representative of three independent experiments.
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GR transcriptional activity is regulated by its ligands, its
interaction with cofactors and posttranslational modifi-
cations [7]. The crosstalk between diverse signalling
pathways results in the activation of several kinases that
phosphorylate GR [10,13,16]. The CDK family of kinases
targets GR for phosphorylation at S203 and S211
whereas the JNK pathway targets S226 [10,13,39]. How-
ever, other kinases including p38 might also be involved
in targeting GR directly or indirectly in a cell type speci-
fic manner [13,17]. One of the most puzzling properties
of this group of steroid hormones is their role in pro-
grammed cell death. Dexamethasone stimulates apopto-
sis in a variety of cells of the immune system and it is
used extensively as a therapeutic agent in leukaemia,
while in most other cell types it exerts anti-apoptotic or
no effects [2]. Several mechanisms have been proposed
to explain the cell type specificity of the apoptotic
effects of glucorticoids including versatile expression of
GR isoforms in different cell types [40] alternative sub-
cellular localisation [41] decreased proteasomal activity
in hormone treated cells [42], and posttranslational
modifications [10,13].
The GR dependent transcriptional regulation of Bcl-2
family members has been proposed as one mechanism of
mediation of the opposing apoptotic effects of dexa-
methasone in different cell types [20,21,27]. The GR
inducible target Bcl-x gene for example exhibits tissue
specific pattern of promoter usage explaining the distinc-
tion between the pro- and anti-apoptotic effects of gluco-
corticoids in lymphoid versus non lymphoid cells [43].
Recent analysis has identified several other members of
the Bcl-2 family to be targeted by GR including Mcl-1
and NOXA and the determination of apoptosis or survi-
val outcome has been attributed to the balance between
pro- and anti-apoptotic genes of the Bcl-2 family [21,44].
In this study we investigated the molecular mechan-
isms underlying the transcriptional effects of glucocorti-
coids and the signalling pathways controlling the Bcl-2
family members. Of particular interest were the NOXA,
Mcl-1 and Bim members of the Bcl-2 family since they
have been implicated in the apoptotic regulation of var-
ious forms of leukaemia [28,31,45,46]. We identified
putative GREs in the promoter regions of Mcl-1 and
NOXA (Figure 1A) and assessed their functionality
using luciferase reporter assays (Figure 1B and 1C). The
changes in luciferase expression driven by the Mcl-1 or
NOXA promoter were mediated by GR since mutated
GREs were unresponsive to hormone treatment (Figure
1B and 1C). Direct GR regulation of other Bcl-2 family
members at the transcriptional level and the role of
these genes in glucocorticoid-induced apoptosis have
been shown in other reports [18,25-27,44].
To monitor the hormone dependent effects on the
expression of Mcl-1, NOXA and Bim mRNA levels we
employed qRT-PCR analysis (Figures 2, 3, 4). Twofold
induction of Mcl-1 mRNA was observed in CEM-C7-14
and CEM-C1-15 cells and five fold in A549 cells. Bim
gene expression increased substantially in A549 and
CEM-C7-14 cells treated by glucocorticoids whereas
only two fold induction of this gene was evident in
CEM-C1-15 cell lines. Noxa gene expression was weakly
inhibited by glucocorticoids in CEM-C7-14 and A549
cells whereas glucocorticoid dependent increase was
observed in CEM-C1-15 cells. Combination of 24 h dex-
amethasone and UV treatment inhibited Mcl-1 in CEM-
C1-15 and induced this gene in CEM-C7-14 cells com-
pared to hormone treatment alone in a JNK dependent
manner (Figures 2 and 3, compare diamonds to squares
at 24 h time point). NOXA was induced by UV treat-
ment in A549 cells at all time points tested and in
CEM-C1-15 cells treated with hormone for 2 and 6 hrs,
whereas repression of this gene was observed in cells
treated with hormone for 24 h when compared to those
cells that were treated with dexamethasone alone
(Figures 3 and 4, compare diamons to squares). In con-
trast, under the same conditions two times elevated
mRNA NOXA levels were observed in CEM-C7-14 cells
at 24 hrs of treatment (Figure 2, compare diamonds to
squares at the 24 h time point). In UV irradiated and
dexamethasone treated for 24 h CEM-C1-15 cells Bim
mRNA levels were increased whereas the opposite was
observed in CEM-C7-14 cells where the Bim mRNA
levels were dramatically decreased under the same con-
ditions (Figures 2 and 3, compare diamonds to squares
at the 24 h time point). The kinase inhibitor completely
abolished the effect of UV on Bim levels in CEM-C1-15
cells and partially abolished that effect in CEM-C7-14
cells (Figures 2 and 3, circles at the 24 h time point).
Our results are in agreement with previously reported
data indicating that glucocorticoids have opposing
effects even on the same gene depending on the cell
type as well as distinguishing characteristics of the sig-
nalling pathways [43]. Similar results in regards to
NOXA gene expression being subject to differential reg-
ulation by different chemotherapeutic agents have
recently been reported [45]. Furthermore, these data
link the effects mediated by glucocorticoids on Bcl-2
family members’ gene expression to the activation of the
JNK pathway.
Given the fact that Mcl-1 has a relatively short half-
life being targeted by NOXA for degradation [33] and
has been implicated in the resistance to GC-mediated
apoptosis [31,32] we next tested the effects of dexa-
methasone treatment on their protein levels (Figure 5).
We observed no changes of Mcl-1, NOXA or Bim
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duration of the hormone treatment (Figure 5B). In
CEM-C7-14 cells the protein levels correlated with the
mRNA levels (Figure 2, diamonds, and Figure 5A).
These results suggest that the regulation of NOXA/Mcl-
1 gene expression by glucocorticoids and potentially of
Mcl-1 stability could be a factor determining protection
against hormone induced programmed cell death in
CEM-C1-15 and sensitivity in CEM-C7-14 cells (Figure
5 and data not shown).
Accumulating evidence suggests potential crosstalk
between the UV irradiation and glucocorticoids in con-
trolling the programmed cell death [47]. We have
recently reported that in UV irradiated cells GR is phos-
phorylated in a JNK dependent manner at S226 [10].
We and other research groups have reported that eleva-
tion of S226 phosphorylation of GR results in the reduc-
tion of the CDK dependent S211 phoshorylation [13,39].
S226 phosphorylation is originally thought to impose
negative whereas S211 stimulating effect on GR tran-
scriptional activity, although target gene specificity of
these phosphorylations is emerging as a new concept
[10,13,39]. To investigate any possible link between
M c l - 1a n d / o rN O X Am R N Ae x p r e s s i o na n dp r e d o m i -
nance of S226 or S211 phosphorylated GR isoforms we
followed the GR phosphorylation status in all three cell
lines treated with UV as shown in Figure 6. Predomi-
nant GR phosphorylation at S211 was observed in
CEM-C7-14 cells compared to S226 phosphorylation
levels normalised to total GR protein levels. On the con-
trary, in CEM-C1-15 cells the S226 phosphorylation
levels were prevailing to those of S211 indicating poten-
tial differential MAPK/CDK pathway activity in the two
cell lines. Another explanation for the distinctive hor-
mone effects in CEM-C7-14 and CEM-C1-15 cell lines
could be the existence of diverse cell line specific GR
isoforms (Figures 6A and 6B respectively). Interestingly
in A549 cells S211 and S246 residues displayed mostly
similar phosphorylation patterns. In A549 and CEM-C1-
15 cells UV irradiation in the absence of hormone
shifted the balance towards S226 phosphorylation (Fig-
ures 6B and 6C).
Taken together these results indicate that phosphory-
lation of GR predominantly at S211 or S226 is a result
of the activation of at least two distinct signalling path-
ways in CEM-C1-15 and CEM-C7-14 cell lines that are
disproportionately targeting GR for phosphorylation in
these two cell lines. It has been suggested that phos-
phorylation plays a crucial role in the regulation of GR
protein stability since mutation of all GR phosphoryla-
tion sites abolished the receptor’s hormone dependent
degradation [11,48]. GR protein stability on the other
hand is a crucial factor in determining its transcrip-
tional activity [11]. It is possible that deregulation of
both the receptor’s protein stability and transcriptional
activity by MAPK and CDK pathways contributes to
the sensitive versus resistant to GCs induced apoptosis
phenotype in different cell lines. Upregulation of GR
protein levels has been detected after short and long
term dexamethasone treatments in CEM-C1-15 cells
(Figure 6B). A possible explanation for the inability of
the accumulated GR to induce apoptosis in CEM-C1-
15 cells (Figure 6B) is that GR phosphorylation at S226
increases the GR protein stability but renders it tran-
scriptionally inactive [10] and data not shown. This
possibility is currently under investigation in our
laboratory.
Consistent with previously published observations,
sub-G1 apoptotic cells were mostly detected in CEM-
C7-14 and not in CEM-C1-15, A549 and HeLa cells
(Figures 7 and 8 and data not shown) [49]. The signifi-
cance of the enhanced NOXA expression in the gluco-
corticoid and UV/hormone mediated apoptosis was
confirmed in CEM-C7-14 cells treated with the protea-
some inhibitor MG-132, which is a potent inducer of
NOXA protein levels [38]. In agreement with previously
published observations [50], the combined treatment of
dexamethasone and MG132 resulted in increased per-
centage of apoptotic CEM-C7-14 cells in comparison to
cells treated with MG-132 alone (Figure 8, compare
black bars 3 and 4). Treatment of CEM-C1-15 cells with
dexamethasone and MG132 did not change the level of
MG-132 induced apoptosis in these cells (Figure 8, com-
pare white bars 3 and 4).
Conclusions
In conclusion, this report describes the complex cell
type specific molecular mechanisms through which glu-
cocorticoid mediated transcription and UV induced sig-
nalling regulate the NOXA/Mcl-1 balance and
determine resistance versus sensitivity to glucocorticoid
induced apoptosis. Given the fact that glucocorticoids
are used extensively in the treatment of ALL and to pre-
vent sickness during chemotherapy the results described
here could be used towards improving glucocorticoid
based therapies [51].
Materials and methods
Cell culture and antibodies
Cells were grown at 37°C and 5% CO2. A549 cells main-
tained in Dulbecco’s minimum essential medium
(DMEM, Gibco) whereas CEM-C1-15 and CEM-C7-14
cells were cultured in RPMI medium and all media sup-
plemented with 10% fetal bovine serum (FBS, Gibco)
and 10 units/ml each of penicillin and streptomycin
(Gibco). DCC treated serum (Hyclone) was used in all
experiments before dexamethasone treatment. The fol-
lowing antibodies were used for western blotting and
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NOXA (Alexis), GR (2F8 generously provided by Dr M.
N. Alexis) [52]. The antibody against S226 phosphory-
lated GR was purchased from Abcam and the GR phos-
pho-S211 was purchased from Cell Signaling. UV and
JNK inhibitor treatments were carried out as described
in [10].
Western blotting
Cells were seeded into 100 mm plates and maintained
in DCC-FBS media. Dex (100 nM for adherent and 1
μM for CEM cells, Sigma) was added at different time-
points. To isolate protein, cells were washed twice with
ice-cold phosphate-buffered saline (PBS) and lysed in
High Salt Lysis buffer (45 mM HEPES pH 7.5, 400
m MN a C l ,1m ME D T A ,1 0 %g l y c e r o l ,0 . 5 %N P - 4 0 ,1
mM DTT, 1 mM PMSF, 1 μg/ml aprotinin, leupeptin
and pepstatin A, 20 mM b-glycerophosphate, 5 mM
sodium pyrophosphate and 2 mM sodium orthovana-
date). Protein levels were measured and equal amounts
of protein were loaded and resolved by SDS PAGE and
Western blotting. Blots were developed with the ECL
substrate according to manufacturer’s instructions
(Pierce). The quantification of the density of the bands
on the blots was performed using Image J software and
the densitometric analysis was performed three times
for each band. The average of these measurements was
used to calculate the density of the total GR (A) and
then the density of the respective actin band (B). The
same was followed for the phospho GR (C) (phospho
GR S211 or phospho GR S226). The results plotted on
t h ed i a g r a ms h o w ni nF i g u r e s6 A ,B ,a n d6 Ca r et h e
products of the following formula: total GR (A)/actin
(B) = X; The ratio of the intensities of total GR versus
actin (X) was then used to determine the relative
intensity of GR phosphoisoforms. Phospho GR (C)/(X)
= relative phosphorylated GR levels (Y), which has
been plotted and shown on the diagrams. The bands
considered for the quantification are indicated with
arrows within the relevant Figure 6.
Quantitative RT-PCR
Adherent cells were grown to 80% confluence and CEM
cells cultured to 1 × 10
7 cells in 30 mm well dishes.
Cells were treated with Dex (100 nM for A549 and 1
μM for CEM cells) for the times indicated. CHX (30
mM) was added 1 hr prior to Dex treatment. Total
mRNA was extracted using the RNeasy plus mini kit
(Qiagen). RNA concentrations were measured and 1
mg/ml of RNA was reverse transcribed according to the
two-step protocol (ABgene) using an oligo-dT primer
(ABgene). The DNA was diluted 4-fold, which was used
for qPCR analysis using SYBR® Green JumpStart™ Taq
ReadyMix™ (Sigma). Analysis was performed using
Opticon monitor 3 software as described previously
[53]. The primers used in this study were:
Rpl19 (F: ATGTATCACAGCCTGTACCTG, R:
TTCTTGGTCTCTTCCTCCTTG),
Mcl-1 (F: TCAAAAACGAAGACGATGTGA, R:
CAAAGGCACCAAAAGAAATGA),
NOXA (F: AAGAAGGCGCGCAAGAAC, R:
TCCTGAGCAGAAGAGTTTGG),
Bim (F: GAGAAGGTAGACAATTGCAG, R:
GACAATGTAACGTAACAGTCG).
Luciferase reporter gene assays
To obtain DNA segments carrying GREs from the Mcl-
1 and NOXA promoters, primers were designed to
amplify a ~400 bp specific region (NOXA GRE (F:
TGGCCTCGCCAAACATT ATGCAA, R:
GAGACTTGGGTAAACAAGC CCAG) and Mcl-1 GRE
(F: GAGCACTGAT GGTGCCACTGCA, R: GAAAC-
CACATTG TCAGGCCTC). The PCR fragments were
then subcloned in the Zero blunt ended TOPO vector
(Invitrogen) and digested using Kpn1 and Sac1 restric-
tion enzymes (Roche). The new PCR fragments includ-
ing restriction sites were ligated into the pGL3
promoter luciferase vector (Invitrogen) and the presence
of the GREs confirmed with DNA sequencing. To
mutate the luciferase vectors, the QuikChange site
directed mutagenesis kit was used according to manu-
facturers guidelines (Stratagene) and mutations con-
firmed with DNA sequencing. The following primers
were designed for mutagenesis:
NOXA GREmutF: (CTTCCCAACTCAAACA CGAA-
GAACTTTCTGGCTGGCACCAGG, NOXA GREmutR:
CCTGGTGCCAGCCAG AAAGTTCTTCGTGTTT-
GAGTTGGGAAG) and Mcl-1 GREmutF: (ATACATG-
GCATAT AAGAAGATCCTAGAACTCAAGGGCTTA-
CAAACCTCTAG) and Mcl-1 GREmutR: (CTAGA-
GGTTTGTAAAGCCCTTGAGTTCTAGGATCTTCT-
TATATG CCA TGTAT). Adherent cells were plated in
30 mm dishes and transfected with indicated plasmids
using Polyfect reagent (Qiagen). Cells were harvested in
reporter lysis solution (Promega) and the luciferase
activity was analysed using luciferin reagent following
the recommended protocol (Promega) using a lumin-
ometer machine [53].
Flow cytometry (FACS analysis)
Cells were seeded into 100 mm plates and maintained
in DCC-FBS media. Dex (1 μM) was added at differ-
ent time points before collection and were centrifuged
at 1,200 rpm for 5 minutes (4°C). Pellets were washed
with ice-cold PBS before adding 1 ml 50% EtOH/PBS
drop-wise, vortexing gently. After washing with PBS,
100 μl of 125 U/ml ribonuclease A (Sigma) and 400
μlo f5 0μg/ml PI (Sigma) were added. The samples
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cycle analysis. The representations and percentages of
cell cycle phases were analysed by Modfit software
[53].
Additional file 1: Supplementary Figure 1. Direct effects of
glucocorticoids on Mcl-1, NOXA and Bim gene expression. CEM C1-15
(A), CEM C7-14 (B) and A549 (C) cells were cultured in DCC-treated
media and incubated with dexamethasone alone for the times indicated
(solid line) or pre-treated with cyclohexamide (30 μM) 1 hour prior to
dexamethasone treatment (dashed line). RNA was extracted, reverse
transcribed and used in a qRT-PCR reaction with primers to analyse the
specific mRNA indicated. All results have been normalised to Rpl19 as an
internal control. Graphs show the average of at least 3 independent
experiments.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-38-
S1.PPT]
Additional file 2: Supplementary Figure 2. Cell cycle profiles of
dexamethasone treated cells. CEM-C1-15, CEM-C7-14 and A549 cells were
treated with dexamethasone for the indicated times. Cells were
harvested, stained with propidium iodide and their cell cycle profile was
determined by FACS analysis.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-38-
S2.PPT]
Additional file 3: Supplementary Figure 3. Cell cycle profiles of
dexamethasone and MG132 treated cells. CEM-C7-14 cells were cultured
in DCC-treated media incubated with dexamethasone (1 μM, 48 hr) and
MG132 (1 μM, 24 hr) and FACS analysis performed. Cell cycle profiles are
representative of three independent experiments.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-38-
S3.PPT]
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